An agonistic anti-Tie2 antibody suppresses the normal-to-tumor vascular transition in the glioblastoma invasion zone
5
조회
0
다운로드
0
인용
0
참고문헌
초록
Tumor progression is intimately associated with the vasculature, as tumor proliferation induces angiogenesis and tumor cells metastasize to distant organs via blood vessels. However, whether tumor invasion is associated with blood vessels remains unknown. As glioblastoma (GBM) is featured by aggressive invasion and vascular abnormalities, we characterized the onset of vascular remodeling in the diffuse tumor infiltrating zone by establishing new spontaneous GBM models with robust invasion capacity. Normal brain vessels underwent a gradual transition to severely impaired tumor vessels at the GBM periphery over several days. Increasing vasodilation from the tumor periphery to the tumor core was also found in human GBM. The levels of vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR2) showed a spatial correlation with the extent of vascular abnormalities spanning the tumor-invading zone. Blockade of VEGFR2 suppressed vascular remodeling at the tumor periphery, confirming the role of VEGF-VEGFR2 signaling in the invasion-associated vascular transition. As angiopoietin-2 (ANGPT2) was expressed in only a portion of the central tumor vessels, we developed a ligand-independent tunica interna endothelial cell kinase 2 (Tie2)-activating antibody that can result in Tie2 phosphorylation in vivo. This agonistic anti-Tie2 antibody effectively normalized the vasculature in both the tumor periphery and tumor center, similar to the effects of VEGFR2 blockade. Mechanistically, this antibody-based Tie2 activation induced VE-PTP-mediated VEGFR2 dephosphorylation in vivo. Thus, our study reveals that the normal-to-tumor vascular transition is spatiotemporally associated with GBM invasion and may be controlled by Tie2 activation via a novel mechanism of action.
Abstract
Tumor progression is intimately associated with the vasculature, as tumor proliferation induces angiogenesis and tumor cells metastasize to distant organs via blood vessels. However, whether tumor invasion is associated with blood vessels remains unknown. As glioblastoma (GBM) is featured by aggressive invasion and vascular abnormalities, we characterized the onset of vascular remodeling in the diffuse tumor infiltrating zone by establishing new spontaneous GBM models with robust invasion capacity. Normal brain vessels underwent a gradual transition to severely impaired tumor vessels at the GBM periphery over several days. Increasing vasodilation from the tumor periphery to the tumor core was also found in human GBM. The levels of vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR2) showed a spatial correlation with the extent of vascular abnormalities spanning the tumor-invading zone. Blockade of VEGFR2 suppressed vascular remodeling at the tumor periphery, confirming the role of VEGF-VEGFR2 signaling in the invasion-associated vascular transition. As angiopoietin-2 (ANGPT2) was expressed in only a portion of the central tumor vessels, we developed a ligand-independent tunica interna endothelial cell kinase 2 (Tie2)-activating antibody that can result in Tie2 phosphorylation in vivo. This agonistic anti-Tie2 antibody effectively normalized the vasculature in both the tumor periphery and tumor center, similar to the effects of VEGFR2 blockade. Mechanistically, this antibody-based Tie2 activation induced VE-PTP-mediated VEGFR2 dephosphorylation in vivo. Thus, our study reveals that the normal-to-tumor vascular transition is spatiotemporally associated with GBM invasion and may be controlled by Tie2 activation via a novel mechanism of action.
참고문헌 (50)
- Carmeliet, P., "Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases", Nat. Rev. Drug Discov, 10, pp.417~427 (2011)
- De Palma, M., "Microenvironmental regulation of tumour angiogenesis", Nat. Rev. Cancer, 17, pp.457~474 (2017)
- Maes, H., "Tumor vessel normalization by chloroquine independent of autophagy", Cancer Cell, 26, pp.190~206 (2014)
- Broekman, M. L., "Multidimensional communication in the microenvirons of glioblastoma", Nat. Rev. Neurol, 14, pp.482~495 (2018)
- Das, S., "Angiogenesis in glioblastoma", N. Engl. J. Med, 369, pp.1561~1563 (2013)
- Hambardzumyan, D., "Glioblastoma : Defining tumor niches", Trends Cancer, 1, pp.252~265 (2015)
- Chae, J. K., "Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization", Arterioscler. Thromb. Vasc. Biol, 20, pp.2573~2578 (2000)
- Gavard, J., "Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia", Dev. Cell, 14, pp.25~36 (2008)
- Winkler, F., "Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation : role of oxygenation, angiopoietin-1, and matrix metalloproteinases", Cancer Cell, 6, pp.553~563 (2004)
- Piao, Y., "Novel MET", TIE2, Neuro. Oncol, pp.2016, 18[DOI]
- Kim, I. K., "Sox7 promotes high-grade glioma by increasing VEGFR2-mediated vascular abnormality", J. Exp. Med, 215, pp.963~983 (2018)
- Park, J. S., "Normalization of tumor vessels by Tie2 activation and Ang2inhibition enhances drug delivery and produces a favorable tumor microenvironment", Cancer Cell, 30, pp.953~967 (2016)
- Cohen, M. H., "FDA drug approval summary : bevacizumab(Avastin)as treatment of recurrent glioblastoma multiforme", Oncologist, 14, pp.1131~1138 (2009)
- Gilbert, M. R., "A randomized trial of bevacizumab for newly diagnosed glioblastoma", N. Engl. J. Med, 370, pp.699~708 (2014)
- Leow, C. C., "MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models", Int. J. Oncol, 40, pp.1321~1330 (2012)
- Lee, E. Q., "NRG", RTOG 1122 : A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma, 2020, pp.126, 2821~2828
- Lee, J. H., "Human glioblastoma arises from subventricular zone cells with low-level driver mutations", Nature, 560, pp.243~247 (2018)
- Li, G., "The VE-PTP inhibitor AKB-9778 improves antitumor activity and diminishes the toxicity of interleukin 2(IL-2)administration", J. Immunother, 42, pp.237~243 (2019)
- Nawroth, R., "VE-PTP and VE-cadherin ectodomains interact to facilitate regulation of phosphorylation and cell contacts", EMBO J, 21, pp.4885~4895 (2002)
- Baumer, S., "Vascular endothelial cell-specific phosphotyrosine phosphatase(VE-PTP)activity is required for blood vessel development", Blood, 107, pp.4754~4762 (2006)
- Huszthy, P. C., "In vivo models of primary brain tumors : pitfalls and perspectives", Neuro. Oncol, 14, pp.979~993 (2012)
- McDermott, D. F., "Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma", Nat. Med, 24, pp.749~757 (2018)
- Jain, R. K., "Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia", Cancer Cell, 26, pp.605~622 (2014)
- Metea, M. R., "Glial cells dilate and constrict blood vessels : a mechanism of neurovascular coupling", J. Neurosci, 26, pp.2862~2870 (2006)
- Chae, S. S., "Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas", Clin. Cancer Res, 16, pp.3618~3627 (2010)
- Wick, W., "Lomustine and bevacizumab in progressive glioblastoma", N. Engl. J. Med, 377, pp.1954~1963 (2017)
- Felcht, M., "Angiopoietin-2 differentially regulates angiogenesis through TIE2and integrin signaling", J. Clin. Invest, 122, pp.1991~2005 (2012)
- Keunen, O., "Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma", Proc. Natl Acad. Sci. USA, 108, pp.3749~3754 (2011)
- Lamszus, K., "Invasion as limitation to anti-angiogenic glioma therapy", Acta Neurochir. Suppl, 88, pp.169~177 (2003)
- Narayana, A., "Antiangiogenic therapy using bevacizumab in recurrent highgrade glioma : impact on local control and patient survival", J. Neurosurg, 110, pp.173~180 (2009)
- Kontos, C. D., "Tyrosine 1101 of Tie2 is the major site of association of p85and is required for activation of phosphatidylinositol 3-kinase and Akt", Mol. Cell Biol, 18, pp.4131~4140 (1998)
- Hayashi, M., "VE-PTP regulates VEGFR2 activity in stalk cells to establish endothelial cell polarity and lumen formation", Nat. Commun, 4, pp.1672~ (2013)
- Shen, J., "Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature", J. Clin. Invest, 124, pp.4564~4576 (2014)
- Mellberg, S., "Transcriptional profiling reveals a critical role for tyrosine phosphatase VE-PTP in regulation of VEGFR2 activity and endothelial cell morphogenesis", Faseb. J, 23, pp.1490~1502 (2009)
- Frye, M., "Interfering with VE-PTP stabilizes endothelial junctions in vivo via Tie-2 in the absence of VE-cadherin", J. Exp. Med, 212, pp.2267~2287 (2015)
- Willam, C., "Tie2 receptor expression is stimulated by hypoxia and proinflammatory cytokines in human endothelial cells", Circ. Res, 87, pp.370~377 (2000)
- Phung, T. L., "Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin", Cancer Cell, 10, pp.159~170 (2006)
- Cui, Y., "Brain endothelial PTEN", AKT, MFSD2A axis regulates bloodbrain barrier permeability, pp.Cell Rep, 2021[DOI]
- Kim, M., "Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1activation", J. Clin. Invest, 126, pp.3511~3525 (2016)
- Alphandery, E., "Glioblastoma treatments : An account of recent industrial developments", Front. Pharmacol, 9, pp.879~ (2018)
- Dickson, P. V., "Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy", Clin. Cancer Res, 13, pp.3942~3950 (2007)
- Reiss, S. N., "Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas", J. Immunother. Cancer, 5, pp.99~ (2017)
- Kurz, S. C., "PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma", Neurology, 91, pp.e1355~e1359 (2018)
- Di Tacchio, M., "Tumor vessel normalization, immunostimulatory reprogramming, and improved survival in glioblastoma with combined inhibition of PD-1, angiopoietin-2, and VEGF", Cancer Immunol. Res, 7, pp.1910~1927 (2019)
- Scholz, A., "Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma", EMBO Mol. Med, 8, pp.39~57 (2016)
- Nayak, L., "Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma", Clin. Cancer Res, 27, pp.1048~1057 (2021)
- Ho, R. L. Y., "Recent advances in glioma therapy: Combining vascular normalization and immune checkpoint blockade", Cancers (Basel), 13, pp.3686~ (2021)
- Iadecola, C., "The neurovascular unit coming of age : A journey through neurovascular coupling in health and disease", Neuron, 96, pp.17~42 (2017)
- Attwell, D., "Glial and neuronal control of brain blood flow", Nature, 468, pp.232~243 (2010)
- Labussiere, M., "Angiopoietin-2 may be involved in the resistance to bevacizumab in recurrent glioblastoma", Cancer Invest, 34, pp.39~44 (2016)